Enjoy a 15% discount on all purchases until the 31st of March 2023 using the promo code EOFWEB22 at check out!

Future of Personalised Healthcare

April 2022

The briefing examines how personalised healthcare market is evolving. The report also provides insights on the countries most ready to use personalised healthcare services, and the potential impact on the pharmaceuticals and medical sectors.

USD 1,325
Request More Information


This report comes in PPT.

Key findings

Consumers prefer personalised services

According to Euromonitor International’s Lifestyles 2021 survey, over 50% of consumers globally prefer goods or services uniquely tailored for them. The shift towards tailored goods and services is expected to support demand for personalised healthcare services and pharmaceuticals.

Healthcare spending continues to rise

According to Euromonitor International’s Lifestyles 2021 survey, 25% of respondents globally plan to increase medical spending. The proportion of respondents planning to spend more on medical services is significantly higher in European, North American and Asian countries.

Digitalisation to offer new opportunities for tech companies

The shift to digital tools can increase the role of IT and tech companies in the value chain. Tech giants could benefit as they have experience in analysing and extracting value from large quantities of data. Similar capabilities will be required when offering personalised health solutions to consumers.

Developed economies lead in personalised healthcare

Developed countries lead in the personalised healthcare transition, thanks to their strong research capabilities, the presence of tech companies and the pharmaceuticals industry. However, emerging markets can improve their healthcare systems by cooperating with tech companies.

Personalised treatment to improve healthcare effectiveness

Strong advancements in targeted therapeutics, cell and gene therapies and advanced diagnostic testing continue to facilitate the development of personalised medicine. A patient-tailored approach is expected to reduce trial-and-error treatments, and improve outcomes and healthcare cost-effectiveness.

Personalised medicines to drive demand for new production methods and collaboration

Pharmaceutical developers and producers are set to embrace new production methods and increase collaboration with contract development and manufacturing companies to reduce costs, save time, and offer the flexibility, scalability and reliability needed in personalised medicine production.

Key findings
Changes in consumer behaviour and new technologies change healthcare landscape
Consumer interest in health increases during the pandemic
Consumers prefer products and services tailored to their needs
Personalised healthcare to increase spending on hi-tech goods and digital tools
IT companies can increase their role in the healthcare value chain
Areas where tech companies can expand
Case study: M2Gen applies Microsoft technologies to power data analytics platform
Case study: Best Buy expands into the personalised health market
Consumers are still reluctant to share personal data with private companies
Companies need to communicate value and collaborate with governments to improve trust
Personalised healthcare index helps to spot key areas for success
Calculation of personalised healthcare index
Countries rank by personalised healthcare index category
Developed markets are among the leaders in the personalised health market for now
Personalised healthcare index by category in selected countries
Case study: UK invests in personalised healthcare due to the ageing population
Case study: Tech giant JD helps to improve personalised healthcare services in China
Personalised medicine to grow in popularity
Personalised medicine to help prevent, diagnose and treat diseases
Benefits of personalised medicine
Oncology therapies continue to dominate the personalised medicine market
The US and China hold strong potential in personalised medicine innovation
Challenges of personalised medicine and examples of potential solutions
Producers embrace non-conventional production methods
Case study: Lonza’s Cocoon Platform enables patient-scale cell therapy manufacturing
Challenges and changes in the personalised medicine supply chain
Case study: Bristol Myers Squibb building a new cell therapy facility in the Netherlands
Case study: Thermo Fisher Scientific introduces new packaging and distribution services
The role of contract development and manufacturing companies in personalised medicine
Key industry takeaways
Challenges to overcome


If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!